Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
Delayed Nasdaq  -  04:00 2022-11-30 pm EST
7.910 USD   +5.33%
11/16Protagonist Therapeutics Reports Granting of Inducement Award
PR
11/10HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintains Buy Rating
MT
11/08PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds
Most relevant news about PROTAGONIST THERAPEUTICS, INC.
11/16Protagonist Therapeutics Reports Granting of Inducement Award
PR
11/10HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintain..
MT
11/08Protagonist Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine ..
CI
11/08Protagonist Therapeutics : Q3 Earnings Snapshot
AQ
11/02Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medic..
PR
11/02Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medic..
CI
09/20Protagonist Therapeutics Reports Granting of Inducement Award
PR
08/25JMP Securities Reinstates Protagonist Therapeutics at Market Outperform With $21 Price ..
MT
08/04Protagonist Therapeutics : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
08/04Protagonist Therapeutics : Q2 Earnings Snapshot
AQ
08/04Protagonist Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six ..
CI
08/04Protagonist Therapeutics : Reports Second Quarter 2022 Financial Results and Provides Corp..
PU
07/19Protagonist Therapeutics Reports Granting of Inducement Award
PR
06/24Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added..
CI
06/24Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropp..
CI
06/24Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added..
CI
06/24Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropp..
CI
06/24Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropp..
CI
06/24Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added..
CI
06/24Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added..
CI
06/24Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropp..
CI
06/24Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added..
CI
06/24Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropp..
CI
06/24Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added..
CI
06/24Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropp..
CI
06/01Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference
PR
05/26Protagonist Therapeutics, Inc. to Present Updated Phase 2 Rusfertide Clinical Results i..
CI
05/18Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reitera..
MT
05/05SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $30 from $50, Keeps Outpe..
MT
05/04Protagonist Therapeutics : Q1 Earnings Snapshot
AQ
05/04Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended Mar..
CI
04/26Protagonist Therapeutics' Shares Plummet After Reporting Trial Data for Inflammatory Bo..
MT
04/26Top Midday Decliners
MT
04/26Top Premarket Decliners
MT
04/26Protagonist Therapeutics : Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ul..
PU
04/25Transcript : Protagonist Therapeutics, Inc. - Special Call
CI
04/25Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in U..
PR
04/25Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in U..
CI
04/19Protagonist Therapeutics : Initial Statement of Beneficial Ownership (Form 3)
PU
04/19Protagonist Therapeutics Reports Granting of Inducement Awards
PR
04/14Sector Update: Health Care Stocks Fading Late, Stop Just Shy of Higher Clo..
MT
04/14Top Midday Decliners
MT
04/14Protagonist Stock Tumbles Thursday as FDA Plans to Rescind Rusfertide Breakthrough Desi..
MT
04/14Sector Update: Health Care Stocks Edging Lower on Thursday
MT
04/14Sector Update: Health Care
MT
04/14Wall Street Treads Water Pre-Bell; Jobless Claims Rise
MT
04/14Sector Update: Health Care Stocks Lean Lower Premarket Thursday
MT
04/14Sector Update: Health Care
MT
04/14Top Premarket Decliners
MT
04/14Protagonist Therapeutics Gets FDA Letter to Rescind Breakthrough Therapy Designation fo..
MT
04/14Protagonist Shares Tumble After FDA Says It May Pull Rusfertide Breakthrough Designatio..
DJ
04/13Protagonist Therapeutics Gets FDA Letter to Rescind Breakthrough Therapy Designation fo..
MT
04/13Protagonist Therapeutics, Inc. Expects to Announce Top-Line Data from Its Phase 2 Clini..
CI
03/28Protagonist Therapeutics Names Asif Ali Finance Chief
MT
03/28Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President ..
PR
03/28Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President ..
CI
03/23Protagonist Therapeutics, Inc. Announces Resignation of Don Kalkofen as Principal Finan..
CI
03/23Protagonist Therapeutics, Inc. Announces Resignation of Don Kalkofen, Chief Financial O..
CI
03/16Protagonist Therapeutics Gets $25 Million Milestone Payment from J&J's Janssen Biotech
MT
03/16Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for D..
PR
02/28Protagonist Therapeutics : Reports Fourth Quarter and Full Year 2021 Financial Results and..
PU
02/28Protagonist Therapeutics : Q4 Earnings Snapshot
AQ
02/28Protagonist Therapeutics, Inc. Reports Earnings Results for the Full Year Ended Decembe..
CI
02/28Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended De..
CI
02/28Protagonist Therapeutics, Inc. Announces Pivotal Phase 3 VERIFY Study of Rusfertide in ..
CI
02/11BTIG Initiates Protagonist Therapeutics at Buy With $55 Price Target
MT
02/10Protagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Co..
PR
01/11Transcript : Protagonist Therapeutics, Inc. Presents at JPMorgan 40th Annual ..
CI
01/04/C O R R E C T I O N -- Protagonist Therapeutics, Inc./
PR
2021Insider Sell: Protagonist Therapeutics
MT
2021Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data
CI
2021Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summi..
PR
2021Protagonist Therapeutics Picks PN-235 for Mid-Stage Trials in Multiple Indications
MT
2021Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Cl..
PR
2021Protagonist Therapeutics Announces Selection of Oral Peptide PN-235 into Phase 2 Clinic..
CI
1  2  3  4  5  6  7Next
Upcoming event on PROTAGONIST THERAPEUTICS, INC.